From: Lane, Cliff (NIH/NIAID) [E]
Sent: Friday, October 2, 2020, 00:04
To: etiakaradze@moh.gov.ge
Cc: tgabunia@moh.gov.ge; Jens Lundgren; tt@aidscenter.ge
Subject: Letter from Drs. Collins and Woodcock
Dear Dr. Tikaradze,
Please see the attached letters from the NIH Director and the Therapeutics Lead for the Operation Warp Speed initiative of the US government. We appreciate the efforts of the
investigators in Georgia to get the ACTIV-3 study. This is a global trial sponsored by the NIH.
Sincerely,
H. Clifford Lane, M.D.
Deputy Director for Clinical Research and Special Projects
National Institute of Allergy and Infectious Diseases
National Institutes of Health